Accelerate Diagnostics (AXDX) Competitors

Accelerate Diagnostics (NASDAQ:AXDX) and Talis Biomedical (NASDAQ:TLIS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Is AXDX or TLIS more profitable?

Talis Biomedical has a net margin of 0.00% compared to Accelerate Diagnostics' net margin of -471.83%. Accelerate Diagnostics' return on equity of 0.00% beat Talis Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accelerate Diagnostics	-471.83%	N/A	-191.66%
Talis Biomedical	N/A	-79.74%	-57.16%

Do insiders & institutionals believe in AXDX or TLIS?

17.1% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 43.8% of Talis Biomedical shares are held by institutional investors. 43.6% of Accelerate Diagnostics shares are held by company insiders. Comparatively, 46.0% of Talis Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has more risk & volatility, AXDX or TLIS?

Accelerate Diagnostics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Talis Biomedical has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Which has better earnings & valuation, AXDX or TLIS?

Accelerate Diagnostics has higher revenue and earnings than Talis Biomedical. Talis Biomedical is trading at a lower price-to-earnings ratio than Accelerate Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accelerate Diagnostics	$11.70M	0.00	-$61.62M	-$2.34	N/A
Talis Biomedical	$300K	8.57	-$62.01M	-$28.02	-0.05

Do analysts recommend AXDX or TLIS?

Given Accelerate Diagnostics' stronger consensus rating and higher possible upside, research analysts plainly believe Accelerate Diagnostics is more favorable than Talis Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accelerate Diagnostics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Talis Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the MarketBeat Community prefer AXDX or TLIS?

Accelerate Diagnostics received 346 more outperform votes than Talis Biomedical when rated by MarketBeat users. Likewise, 58.39% of users gave Accelerate Diagnostics an outperform vote while only 37.50% of users gave Talis Biomedical an outperform vote.

Company	Underperform	Outperform
Accelerate Diagnostics	Outperform Votes 355 58.39%	Underperform Votes 253 41.61%
Talis Biomedical	Outperform Votes 9 37.50%	Underperform Votes 15 62.50%

Does the media favor AXDX or TLIS?

In the previous week, Accelerate Diagnostics had 2 more articles in the media than Talis Biomedical. MarketBeat recorded 2 mentions for Accelerate Diagnostics and 0 mentions for Talis Biomedical. Talis Biomedical's average media sentiment score of 0.00 beat Accelerate Diagnostics' score of -0.71 indicating that Talis Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Accelerate Diagnostics	Negative
Talis Biomedical	Neutral

Summary

Accelerate Diagnostics beats Talis Biomedical on 11 of the 17 factors compared between the two stocks.